NDA 211243 · Janssen Pharms
Spravato
Esketamine Hydrochloride · Nasal
Breakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Mar 5, 2019
Approved uses
3
Original approval plus efficacy supplements
Registered trials
321
30 Phase 3, 49 recruiting
FAERS reports
18,798
13,122 serious, 736 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEDATION; DISSOCIATION; RESPIRATORY DEPRESSION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS WARNING: SEDATION; DISSOCIATION; RESPIRATORY DEPRESSION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Risk for sedation, dissociation, and respiratory depression after administration. Monitor patients for at least two hours after administration. ( 5.1 , 5.2 , 5.3 ) Potential for abuse and misuse. Consider the risks and benefits of prescribing SPRAVATO prior to using in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse. ( 5.4 ) SPRAVATO is only available through a restricted program called the SPRAVATO REMS. ( 5.5 ) Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all...
What it is approved for
From the label in effect Sep 22, 2026.
SPRAVATO is indicated for the treatment of: Treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant SPRAVATO is a non-competitive N -methyl D -aspartate (NMDA) receptor antagonist indicated for the treatment of: Treatment-resistant depression (TRD) in adults, as monotherapy or in conjunction with an oral antidepressant. ( 1 ) Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant. ( 1 ) Limitations of Use: The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO. ( 1 ) SPRAVATO is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO as an anesthetic agent have not been established. ( 1 ) Limitations of Use The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated [see Clinical Studies (14.2) ] . Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO. SPRAVATO is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO as an anesthetic agent have not been established.
Mechanism: Esketamine, the S-enantiomer of racemic ketamine, is a non-selective, non-competitive antagonist of the N -methyl- D -aspartate (NMDA) receptor, an ionotropic glutamate receptor. The mechanism by which esketamine exerts its antidepressant effect is unknown. The major circulating metabolite of esketamine (noresketamine) demonstrated activity at the same receptor with less affinity.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 17, 2025 Supplement 16 · Efficacy · priority review Breakthrough therapyLabelLetter
- Jul 31, 2020 Supplement 4 · Efficacy Breakthrough therapyLetterLabelReview
- Mar 5, 2019 Original approval · Type 2 - New Active Ingredient · priority review Breakthrough therapyLabelLetterREMS
1 products under this application
- SPRAVATO · ESKETAMINE HYDROCHLORIDE EQ 28MG BASE · SPRAY, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Esketamine" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy Evaluation of S (+) - Ketamine in AdultsPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04837170 · 12,000 participants (planned) · Start May 1, 2021 · Primary completion Jun 1, 2022
Drug: Conventional therapy + S (+)-Ketamine; Conventional therapy · For: Postoperative Pain; Adults; Anesthesia
- Safety and Efficacy Evaluation of S (+) - Ketamine in ChildrenPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04834427 · 3,000 participants (planned) · Start Apr 20, 2022 · Primary completion Dec 1, 2024
Drug: Conventional therapy + S (+)-Ketamine; Conventional therapy · For: S-ketamine; Esketamine; Acute Pain and 6 more
Sites: Beijing, China
- Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After SurgeryPivotal-lookingNot yet recruiting
Peking University First HospitalAcademic, hospital or other
NCT07576517 · 1,996 participants (planned) · Start Oct 2026 · Primary completion Dec 2029
Drug: Dex-Esk; Placebo · For: Older Patients; Surgery; Dexmedetomidine and 3 more
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 6 sites in all
- Long-term Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After SurgeryPivotal-lookingNot yet recruiting
Peking University First HospitalAcademic, hospital or other
NCT07576543 · 1,996 participants (planned) · Start Oct 2026 · Primary completion Dec 2030
Drug: Dex-Esk; Placebo · For: Older Patients; Surgery; Dexmedetomidine and 4 more
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 6 sites in all
- Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder DiscomfortPivotal-lookingRecruiting
Peking University First HospitalAcademic, hospital or other
NCT06399185 · 1,740 participants (planned) · Start Jun 6, 2024 · Primary completion Apr 2027
Drug: Normal saline; Dexmedetomidine and 2 more · For: Urinary Catheter; Catheter-related Bladder Discomfort; Dexmedetomidine and 1 more
Sites: Beijing, China; Shenzhen, China
- Effect of Low-dose EsketaMine on dElirium in High-risk Elderly Patients uNdergoing elecTive Surgery (ELEMENT)Pivotal-lookingRecruiting
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
NCT06817239 · 1,670 participants (planned) · Start Feb 12, 2025 · Primary completion Jun 2027
Drug: Esketamine; Normal saline · For: Delirium in Old Age; Delirium, Postoperative; Anesthesia and 4 more
Sites: Fuzhou, China; Guangzhou, China; Ganzhou, China · 6 sites in all
- Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU PatientsPivotal-lookingNot yet recruiting
Peking University First HospitalAcademic, hospital or other
NCT06468436 · 1,508 participants (planned) · Start Nov 2025 · Primary completion Dec 1, 2029
Drug: Dexmedetomidine-Esketamine Combination; Dexmedetomidine · For: Aged; Intensive Care Units; Ventilators, Mechanical and 3 more
Sites: Beijing, China; Tianjin, China · 3 sites in all
- A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02782104 · 1,148 participants · Start Jun 9, 2016 · Primary completion Dec 30, 2022
Drug: Esketamine Nasal Spray · For: Depressive Disorder, Treatment-Resistant
Sites: Birmingham, Alabama; Little Rock, Arkansas; Garden Grove, California · 173 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dissociation3,903
- sedation2,816
- suicidal ideation1,446
- drug ineffective1,134
- nausea1,006
- depression956
- hypertension917
- product dose omission issue852
- hospitalisation850
- anxiety775
- vomiting764
- dizziness670
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 677 |
| 2020 | 1,004 |
| 2021 | 1,249 |
| 2022 | 1,463 |
| 2023 | 2,111 |
| 2024 | 3,262 |
| 2025 | 6,094 |
| 2026 | 2,933 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Spravato (Esketamine HCl)
2024 spending
$128M
Beneficiaries
5,542
84,544 claims
Per beneficiary
$23,121
$394.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $21,836,746 |
| 2021 | $32,871,804 |
| 2022 | $49,999,095 |
| 2023 | $80,470,297 |
| 2024 | $128,139,293 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.
Fountoulakis KN, Saitis A, Schatzberg AF · Am J Psychiatry 2025 · Systematic Review, Meta-Analysis
- Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.
Janik A, Qiu X, Lane R, et al. · JAMA Psychiatry 2025 · Randomized Controlled Trial, Multicenter Study
- Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A, Bitter I, Buyze J, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V, Daly EJ, Trivedi M, et al. · Am J Psychiatry 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Bahji A, Vazquez GH, Zarate CA · J Affect Disord 2021 · Meta-Analysis, Systematic Review
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ, Trivedi MH, Janik A, et al. · JAMA Psychiatry 2019 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.